Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Thesan Pharmaceuticals (San Clemente, CA), a preclinical biopharmaceutical company focused on dermatological disorders, closed a $16M Series A financing. Participants include Novo Ventures and Novartis Venture Funds. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Principia Biopharma (San Francisco, CA), a biopharmaceutical company focused on immunology, autoimmune diseases and oncology, closed a $12.5M Series A financing, bringing the total round to $36.6M. Participants include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SR One and Mission Bay Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation […]

GeneWeave Biosciences (San Jose, CA) a development-stage molecular diagnostic company focused on using bacterial DNA for the detection of pathogens, closed a $12M Series A financing. Participants include Decheng Capital, Claremont Creek Ventures and X/Seed Capital. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Sequent Medical (Aliso Viejo, CA) a commercial-stage medical device company focused on endovascular embolic coils devices for ruptured and non-ruptured intracranial aneurysms, closed a $26M Series C financing. Participants include Delphi Ventures, Versant Ventures, US Venture Partners and Domain Associates. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Aragon Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on the treatment of hormone-resistant cancers, with an intital focuse on prostate and breast cancer, closed a $42M Series C financing. Participants include Aisling Capital, OrbiMed, Column Group and Topspin Partners. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

HemaQuest Pharmaceuticals (San Diego,CA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease and beta thalassemia closed a $13M Series B financing, bringing the total round to $25M. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. Note: Closing out 1Q deals. Thanx for your patience as […]

Jiff (Palo Alto, CA) a commercial-stage health IT company focused on a HIPAA-compliant private healthcare social network and digital health application platform, closed a $7.5M Series A financing. Participants include Aeris Capital and Aberdare Ventures.

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

Relievant Medsystems (Redwood City, CA) a clinical-stage medical device company focused on a device for radio frequency nerve ablation for chronic axial low back pain, closed a $30M Series D financing. Participants include New Enterprise Associates, Morgenthaler Ventures, Emergent Medical Partners, Canaan Partners and Onset Ventures.

Genalyte (San Diego, CA) a clinical-stage medical device company focused on next-generation multiplexing technology, hardware and software for antibody, protein and nucleic acid assays for autoimmune diseases and other diseases, closed a $11.8M Series A financing. Participants include Redmile Group and Claremont Creek Ventures.

S.E.A. Medical Systems (Santa Clara, CA) a development-stage medical device company focused on IV drug, concentration and diluent monitoring devices for safety and prevention of drug errors, closed a $3M Series B financing. Participants include JK&B Capital.

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

Natura, f/k/a Gene Security Network (Redwood City, CA) a clinical-stage diagnostic company focused on non-invasive prenatal DNA diagnostic tests for gene translocations, aneuploidy, single genes and diseases such as Down Syndrome, closed a $20M Series D financing. Participants include Lightspeed Venture Partners, Claremont Creek Ventures and Sequoia Capital.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...